Trial Profile

Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoledronic acid (Primary)
Indications Advanced breast cancer; Bone metastases; Multiple myeloma
Focus Biomarker; Pharmacokinetics

Most Recent Events

29 Apr 2013 New information source identified and integrated European Clinical trials database
29 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials database.
06 Jun 2011 Planned End Date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com